Insulet (NASDAQ:PODD) Price Target Lowered to $208.00 at Bank of America

Insulet (NASDAQ:PODD) had its price target decreased by Bank of America from $288.00 to $208.00 in a note issued to investors on Monday,Benzinga reports. The firm presently has a “buy” rating on the medical instruments supplier’s stock. Bank of America‘s price objective points to a potential upside of 36.36% from the stock’s current price.

Other equities research analysts have also recently issued research reports about the company. Truist Financial lowered their target price on Insulet from $315.00 to $250.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. Evercore decreased their price objective on Insulet from $240.00 to $200.00 in a report on Thursday, May 7th. Sanford C. Bernstein decreased their target price on shares of Insulet from $330.00 to $200.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. BTIG Research cut their price target on shares of Insulet from $320.00 to $260.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. Finally, Raymond James Financial decreased their price target on shares of Insulet from $355.00 to $263.00 in a report on Thursday, May 7th. Twenty research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Insulet currently has an average rating of “Moderate Buy” and a consensus target price of $254.96.

Insulet Trading Up 3.4%

Shares of PODD stock traded up $5.08 during trading on Monday, hitting $152.54. 773,593 shares of the stock traded hands, compared to its average volume of 1,131,386. The firm has a market capitalization of $10.57 billion, a P/E ratio of 35.58, a price-to-earnings-growth ratio of 1.20 and a beta of 1.20. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81. The firm’s fifty day moving average price is $199.93 and its 200-day moving average price is $256.50. Insulet has a 52-week low of $145.59 and a 52-week high of $354.88.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. The business had revenue of $761.70 million for the quarter, compared to analyst estimates of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The company’s revenue was up 33.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.02 earnings per share. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, research analysts forecast that Insulet will post 6.44 earnings per share for the current fiscal year.

Insider Buying and Selling at Insulet

In other Insulet news, Director Michael R. Minogue acquired 2,030 shares of the business’s stock in a transaction that occurred on Wednesday, February 25th. The stock was acquired at an average price of $246.23 per share, with a total value of $499,846.90. Following the transaction, the director owned 17,483 shares of the company’s stock, valued at approximately $4,304,839.09. This trade represents a 13.14% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.36% of the company’s stock.

Hedge Funds Weigh In On Insulet

Several large investors have recently made changes to their positions in the business. NewEdge Advisors LLC grew its stake in shares of Insulet by 44.8% during the first quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier’s stock worth $54,000 after purchasing an additional 64 shares during the period. Cresset Asset Management LLC boosted its position in Insulet by 7.3% during the second quarter. Cresset Asset Management LLC now owns 2,587 shares of the medical instruments supplier’s stock valued at $813,000 after purchasing an additional 177 shares during the last quarter. Cerity Partners LLC lifted its stake in Insulet by 68.7% in the second quarter. Cerity Partners LLC now owns 17,262 shares of the medical instruments supplier’s stock valued at $5,423,000 after acquiring an additional 7,030 shares during the last quarter. Sei Investments Co. lifted its position in shares of Insulet by 27.4% in the second quarter. Sei Investments Co. now owns 137,643 shares of the medical instruments supplier’s stock valued at $43,245,000 after buying an additional 29,584 shares during the last quarter. Finally, Treasurer of the State of North Carolina lifted its stake in shares of Insulet by 2.5% during the 2nd quarter. Treasurer of the State of North Carolina now owns 32,752 shares of the medical instruments supplier’s stock worth $10,290,000 after buying an additional 791 shares during the last quarter.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.